,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2005', 'fs': 'Apr 2005', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0k2AB'}, 'Id': 'a0POZ00000B4g0k2AB', 'Event_Date__c': '2005-04-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Apr 2005', 'Status_History__c': 'a132P000000Ap2NQAS'}, 'change': None}]",Apr 2005,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2005', 'fs': 'Apr 2005', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0l2AB'}, 'Id': 'a0POZ00000B4g0l2AB', 'Event_Date__c': '2005-04-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Apr 2005', 'Status_History__c': 'a132P000000Ap2UQAS'}, 'change': None}, {'Summary': {'s': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Cancer Treatments Subcommittee of PTAC recommended that this application be declined at its meeting in May 2005</span></p>', 'fs': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Cancer Treatments Subcommittee of PTAC recommended that this application be declined at its meeting in May 2005</span></p>', 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: rgb(62, 62, 60);"">The subcommittee recommended that the application should not be progressed until survival and quality of life data are provided for use as an alternative to rituximab, and following rituximab failure.</span></p>', 'fs': '<p><span style=""color: rgb(62, 62, 60);"">The subcommittee recommended that the application should not be progressed until survival and quality of life data are provided for use as an alternative to rituximab, and following rituximab failure.</span></p>', 'change': None}, 'Published_Discussion': {'s': '<p style=""text-align: justify;"">The subcommittee considered that the best evidence for the efficacy of ibritumomab came from a controlled study comparing ibritumomab with rituximab, in rituximab naïve patients. Ibritumomab demonstrated a better overall response rate (80% vs 56%), although other outcome measures such as time to progression were similar for ibritumomab and rituximab (11.2 months vs 10.1 months, respectively).</p><p style=""text-align: justify;"">\xa0</p><p style=""text-align: justify;"">The subcommittee noted that this application was for use of ibritumomab following failure of rituximab therapy. Although there were small uncontrolled studies of ibritumomab in this setting, the subcommittee considered that it was not clear from the data what benefit ibritumomab has on outcomes such as survival and quality of life.\xa0The subcommittee considered that quality of life was a particularly important consideration in this palliative setting.</p><p style=""text-align: justify;"">\xa0</p><p style=""text-align: justify;"">The subcommittee considered that when trying to establish the place of ibritumomab in the management of indolent B-cell NHL, it would be important to consider the exclusions to the use of the product and the less favourable adverse effect profile compared with rituximab. Myleosuppression caused by ibritumomab could prevent further courses of chemotherapy being an option for many patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The subcommittee considered the data to be immature for this product, and that it is not currently possible to determine the best place for it in the management of low-grade NHL.\xa0</p>', 'fs': '<p style=""text-align: justify;"">The subcommittee considered that the best evidence for the efficacy of ibritumomab came from a controlled study comparing ibritumomab with rituximab, in rituximab naïve patients. Ibritumomab demonstrated a better overall response rate (80% vs 56%), although other outcome measures such as time to progression were similar for ibritumomab and rituximab (11.2 months vs 10.1 months, respectively).</p><p style=""text-align: justify;"">\xa0</p><p style=""text-align: justify;"">The subcommittee noted that this application was for use of ibritumomab following failure of rituximab therapy. Although there were small uncontrolled studies of ibritumomab in this setting, the subcommittee considered that it was not clear from the data what benefit ibritumomab has on outcomes such as survival and quality of life.\xa0The subcommittee considered that quality of life was a particularly important consideration in this palliative setting.</p><p style=""text-align: justify;"">\xa0</p><p style=""text-align: justify;"">The subcommittee considered that when trying to establish the place of ibritumomab in the management of indolent B-cell NHL, it would be important to consider the exclusions to the use of the product and the less favourable adverse effect profile compared with rituximab. Myleosuppression caused by ibritumomab could prevent further courses of chemotherapy being an option for many patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The subcommittee considered the data to be immature for this product, and that it is not currently possible to determine the best place for it in the management of low-grade NHL.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p style=""text-align: justify;"">The subcommittee considered an application from Schering NZ for the listing of ibritumomab for the treatment of adult patients with CD20 positive indolent B-cell non-Hodgkin’s lymphoma who had failed rituximab therapy.</p><p><br></p>', 'fs': '<p style=""text-align: justify;"">The subcommittee considered an application from Schering NZ for the listing of ibritumomab for the treatment of adult patients with CD20 positive indolent B-cell non-Hodgkin’s lymphoma who had failed rituximab therapy.</p><p><br></p>', 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2005', 'fs': 'May 2005', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 13 May 2005.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 13 May 2005.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0m2AB'}, 'Id': 'a0POZ00000B4g0m2AB', 'Event_Date__c': '2005-05-13', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 13 May 2005.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Summary__c': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Cancer Treatments Subcommittee of PTAC recommended that this application be declined at its meeting in May 2005</span></p>', 'Formatted_Date__c': 'May 2005', 'Published_Recommendation__c': '<p><span style=""color: rgb(62, 62, 60);"">The subcommittee recommended that the application should not be progressed until survival and quality of life data are provided for use as an alternative to rituximab, and following rituximab failure.</span></p>', 'Published_Application__c': '<p style=""text-align: justify;"">The subcommittee considered an application from Schering NZ for the listing of ibritumomab for the treatment of adult patients with CD20 positive indolent B-cell non-Hodgkin’s lymphoma who had failed rituximab therapy.</p><p><br></p>', 'Published_Discussion__c': '<p style=""text-align: justify;"">The subcommittee considered that the best evidence for the efficacy of ibritumomab came from a controlled study comparing ibritumomab with rituximab, in rituximab naïve patients. Ibritumomab demonstrated a better overall response rate (80% vs 56%), although other outcome measures such as time to progression were similar for ibritumomab and rituximab (11.2 months vs 10.1 months, respectively).</p><p style=""text-align: justify;"">\xa0</p><p style=""text-align: justify;"">The subcommittee noted that this application was for use of ibritumomab following failure of rituximab therapy. Although there were small uncontrolled studies of ibritumomab in this setting, the subcommittee considered that it was not clear from the data what benefit ibritumomab has on outcomes such as survival and quality of life.\xa0The subcommittee considered that quality of life was a particularly important consideration in this palliative setting.</p><p style=""text-align: justify;"">\xa0</p><p style=""text-align: justify;"">The subcommittee considered that when trying to establish the place of ibritumomab in the management of indolent B-cell NHL, it would be important to consider the exclusions to the use of the product and the less favourable adverse effect profile compared with rituximab. Myleosuppression caused by ibritumomab could prevent further courses of chemotherapy being an option for many patients.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The subcommittee considered the data to be immature for this product, and that it is not currently possible to determine the best place for it in the management of low-grade NHL.\xa0</p>', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Ap2qQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2005', 'fs': 'Aug 2005', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 17 August 2005.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 17 August 2005.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0n2AB'}, 'Id': 'a0POZ00000B4g0n2AB', 'Event_Date__c': '2005-08-17', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 17 August 2005.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Aug 2005', 'Status_History__c': 'a132P000000Ap45QAC'}, 'change': None}]",Apr 2005,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,,,False,False
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0o2AB'}, 'Id': 'a0POZ00000B4g0o2AB', 'Event_Date__c': '2013-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqVkQAK'}, 'change': None}]",Nov 2013,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0p2AB'}, 'Id': 'a0POZ00000B4g0p2AB', 'Event_Date__c': '2023-12-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004kHejYAE'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0q2AB'}, 'Id': 'a0POZ00000B4g0q2AB', 'Event_Date__c': '2024-02-12', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000006lrK2YAI'}, 'change': None}]",Feb 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4g0r2AB'}, 'Id': 'a0POZ00000B4g0r2AB', 'Event_Date__c': '2024-07-29', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000CfjWwYAJ'}, 'change': None}]",Jul 2024,False,True
